Deutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with UnApril 26, 2024 10:38 AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $48 at BMO CapitalApril 26, 2024 8:49 AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $37 at Morgan StanleyApril 26, 2024 8:35 AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $60 at JPMorganApril 26, 2024 7:52 AM Bristol-Myers Squibb Co. (BMY) PT Lowered to $64 at Truist SecuritiesApril 25, 2024 5:05 PM Form 10-Q BRISTOL MYERS SQUIBB CO For: Mar 31April 25, 2024 12:39 PM Bristol Myers posts quarterly loss, lays out $1.5 billion cost-saving planApril 25, 2024 7:53 AM Midday movers: Meta, IBM, Caterpillar fall; Chipotle risesApril 25, 2024 7:51 AM Form 8-K BRISTOL MYERS SQUIBB CO For: Apr 25April 25, 2024 7:48 AM Bristol-Myers Squibb (BMY) stock slips despite earnings beatApril 25, 2024 7:09 AM Bristol-Myers Squibb (BMY) Tops Q1 EPS by 7c, Beats on RevenueApril 25, 2024 7:00 AM Bristol Myers Squibb Reports First Quarter Financial Results for 2024April 25, 2024 6:59 AM